Till Capital Corp is a holding company operating through the insurance segment. Through its subsidiaries, it conducts the insurance and reinsurance business. Its geographical segments are Canada, and United States. The company operates in a single segment, that being investments.
相关临床试验
4
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2018
终止
3
75.0%
撤回
1
25.0%
暂无批准数据
- Oryon Cell Therapies has appointed Kenny Choi, Ph.D., as Chief Technical Officer to lead technical operations and CMC strategy for its autologous neuron replacement medicines. - Dr. Choi brings more than fifteen years of cell therapy manufacturing experience, contributing to over a dozen INDs and three BLAs for autologous cell therapies. - He will oversee transfer of the autologous iPSC-derived dopaminergic neuron manufacturing process from Mass General Brigham to Oryon's own facilities for late-stage development and commercial launch. - Oryon's lead program is in a Phase 1/2a trial for Parkinson's disease, with interim data showing sustained motor improvements in all treated participants.
- Instil Bio's subsidiary Axion Bio terminated its licensing agreement with ImmuneOnco Biopharmaceuticals and discontinued development of AXN-2510, a PD-L1xVEGF bispecific antibody for solid tumors. - The decision reverses all global development and commercial rights outside Greater China back to ImmuneOnco, ending a partnership that began in August 2024 with potential milestone payments exceeding $2 billion. - AXN-2510 had shown promising interim results in Chinese Phase 2 trials, with 80% partial response rates in squamous NSCLC patients and 46% in non-squamous NSCLC patients. - The termination represents a significant strategic shift for Instil Bio, impacting its oncology pipeline and causing shares to plummet 52.48% to a new 52-week low.
- The tumor-infiltrating lymphocyte (TIL) therapy market is transitioning from experimental to commercial use following the FDA approval of Iovance Biotherapeutics' AMTAGVI for advanced melanoma in 2024. - Multiple companies including Obsidian Therapeutics, KSQ Therapeutics, and Biosyngen are advancing novel TIL therapies through early-stage trials targeting diverse solid tumor indications beyond melanoma. - The market is expected to surge significantly by 2034, driven by expanding applications to cervical cancer, non-small cell lung cancer, endometrial cancer, and other solid tumors. - Key technological advances including CRISPR gene editing, automated manufacturing platforms, and reduced production times are addressing traditional scalability and cost challenges.
- Instil Bio has appointed Jamie Freedman, M.D., Ph.D., as Chief Medical Officer to lead development of AXN-2510, a novel PD-L1xVEGF bispecific antibody for solid tumors. - Dr. Freedman brings over 20 years of biopharmaceutical leadership experience and has contributed to 15 drug approvals across multiple therapeutic areas. - The appointment strengthens Instil Bio's clinical leadership as the company advances AXN-2510, which Dr. Freedman believes has potential to redefine standard of care for solid tumors.
- Instil Bio shares rose following the announcement of an updated clinical development strategy for IMM2510/AXN-2510, a novel PD-(L)1xVEGF bispecific antibody developed with ImmuneOnco Biopharmaceuticals. - The companies plan to initiate a Phase 1b/2 clinical trial for their experimental immunotherapy, targeting specific cancer indications with high unmet medical needs. - This strategic advancement represents a significant milestone in Instil Bio's oncology pipeline, potentially offering a new treatment approach by simultaneously targeting two critical cancer pathways.
- Instil Bio's stock jumped 48.4% following positive updates on IMM2510/AXN-2510, a novel PD-L1xVEGF bispecific antibody showing 23% objective response rate in relapsed/refractory non-small cell lung cancer. - The Phase 2 trial of IMM2510/AXN-2510 in first-line NSCLC in China is progressing well, with enrollment expected to complete by Q3 2025 and initial results anticipated later this year. - Instil Bio plans to expand clinical development with a U.S. Phase 1b/2 trial in solid tumors by 2025, potentially accelerating the global development pathway for this promising immunotherapy.
- ImmuneOnco has dosed the first patient in a Phase 1b/2 trial of IMM2510/SYN-2510 with chemotherapy for advanced non-small cell lung cancer (NSCLC) in China. - Instil Bio anticipates initiating a U.S. clinical trial of SYN-2510/IMM2510 in first-line NSCLC patients in combination with chemotherapy in the second half of 2025. - Initial clinical data from ImmuneOnco's trial, including data for first-line NSCLC patients, is expected in the second half of 2025, potentially informing Instil's global strategy.
